Intact Investment Management Inc. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 3.4% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 408,700 shares of the biopharmaceutical company’s stock after selling 14,300 shares during the quarter. Intact Investment Management Inc.’s holdings in Pfizer were worth $14,832,000 as of its most recent filing with the SEC.
Several other hedge funds have also made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Pfizer by 1.5% in the 1st quarter. BlackRock Inc. now owns 459,530,944 shares of the biopharmaceutical company’s stock valued at $16,308,754,000 after buying an additional 6,785,335 shares in the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Pfizer by 1.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 61,720,550 shares of the biopharmaceutical company’s stock valued at $2,190,462,000 after buying an additional 889,094 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Pfizer by 11.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company’s stock valued at $1,674,223,000 after buying an additional 4,998,981 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of Pfizer by 4.4% in the 2nd quarter. Fisher Asset Management LLC now owns 39,445,117 shares of the biopharmaceutical company’s stock valued at $1,431,069,000 after buying an additional 1,671,311 shares in the last quarter. Finally, LSV Asset Management raised its stake in shares of Pfizer by 4.2% in the 1st quarter. LSV Asset Management now owns 35,801,094 shares of the biopharmaceutical company’s stock valued at $1,270,580,000 after buying an additional 1,440,402 shares in the last quarter. Institutional investors own 68.91% of the company’s stock.
In other Pfizer news, insider Laurie J. Olson sold 10,214 shares of the stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the sale, the insider now owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Loretta V. Cangialosi sold 26,814 shares of the stock in a transaction dated Wednesday, August 1st. The stock was sold at an average price of $40.16, for a total transaction of $1,076,850.24. Following the sale, the vice president now directly owns 102,360 shares in the company, valued at approximately $4,110,777.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 761,230 shares of company stock worth $29,054,690. Insiders own 0.06% of the company’s stock.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. The business had revenue of $13.47 billion during the quarter, compared to analysts’ expectations of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the company posted $0.67 EPS. equities research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 4th. Shareholders of record on Friday, August 3rd were issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date was Thursday, August 2nd. Pfizer’s dividend payout ratio is currently 51.32%.
A number of equities analysts have recently issued reports on PFE shares. JPMorgan Chase & Co. restated a “$37.66” rating on shares of Pfizer in a research note on Wednesday, July 18th. Cantor Fitzgerald set a $45.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, July 11th. Morgan Stanley restated a “buy” rating and issued a $43.00 price objective on shares of Pfizer in a research note on Monday, June 11th. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price for the company in a research report on Tuesday, July 3rd. Finally, BMO Capital Markets reiterated a “buy” rating and set a $42.00 target price on shares of Pfizer in a research report on Thursday, July 19th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $41.89.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.